Danaher Corporation vs Vanguard S&P 500 ETF — how do they compare? Danaher Corporation trades at $206.12 (market cap $145.83B), while Vanguard S&P 500 ETF trades at $710.12. The key difference: Danaher Corporation pays a 0.77% dividend while Vanguard S&P 500 ETF pays none, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Danaher Corporation nearer its low. Which is the better fit depends on your goals.
| DHR | VOO | |
|---|---|---|
Market Cap | $145.83B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $242.05 | $710.71 |
52-Week Low | $161.91 | $580.93 |
Enterprise Value | $168.04B | — |
Dividend Yield | 0.77% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →